Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 1/20 | 0.38 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973963 | 0.92 | MCHR1 (0.40) | KMT2ALMNAENPP2NPC1CPT2 | |
| SCHEMBL21189492 | 0.88 | CHRM3 (0.40) | LMNACPT2CPT1ACPT1BCHRM3 | |
| SCHEMBL19973909 | 0.87 | IDO1 (0.40) | KMT2ALMNAENPP2CPT2CPT1A | |
| SCHEMBL19973907 | 0.87 | IDO1 (0.40) | KMT2ALMNAENPP2CPT2CPT1A | |
| SCHEMBL21189310 | 0.86 | MAPT (0.40) | LMNACPT2CPT1ACPT1BCHRM3 | |
| SCHEMBL21189385 | 0.85 | CHRM3 (0.38) | KMT2ALMNAENPP2CPT2CPT1A | |
| SCHEMBL21189308 | 0.84 | MAPT (0.49) | KMT2ALMNAMAPTTP53MEN1 | |
| SCHEMBL19973622 | 0.84 | CHRM1 (0.47) | KMT2ACHRM3MEN1 | |
| Hydrochloric Acid SCHEMBL19973889 | 0.84 | CHRM1 (0.46) | KMT2ACHRM3MEN1 | |
| SCHEMBL21189275 | 0.81 | NPC1 (0.46) | KMT2ANPC1CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | KMT2A 155/4885LMNA 477/4885ENPP2 3131/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | KMT2A 155/4885LMNA 477/4885ENPP2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.